Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds
Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1.
Key Moments From the Change Healthcare Cyberattack Senate Hearing
Andrew Witty, CEO of UnitedHealth Group, faced bipartisan outrage from senators on the Senate Finance Committee angered by his company's cybersecurity failures. Here were the key moments from the hearing on Wednesday.
Kaiser Permanente Is Deploying Innovaccer’s Value-Based Care AI Across Washington
Kaiser Permanente is deploying Innovaccer’s healthcare AI platform and population health management tools to support better value-based care — starting with its Washington market and potentially expanding to new markets in the future.
How Companies Can Improve Their Learning and Development Strategy and Why it is Essential in the Life Sciences Space
Some specific topics that should be prioritized at all levels
Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition
Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.